Contact:
Robert L. Villier
215-707-4839
[email protected]
As reported in the April issue of Clinical Infectious Diseases, a study led by Dr. Paul Nyirjesy, director of the Temple University Vaginitis Referral Center, has resulted in a second line of defense for the treatment of vaginal trichomoniasis. This study has confirmed the effectiveness of the antibiotic paromomycin in curing difficult-to-treat cases.
Vaginal trichomoniasis is a common infection, affecting an estimated 3 million women annually. Metronidazole -- or Flagyl, as it is commonly called -- has been the only approved treatment is the United States for years. It continues to be very effective in treating more than 95 percent of cases. However, there are these challenging medical situations where women donÃt respond to the treatment, even at higher doses.
This study is the largest to date and the only one to find a cure for treatment-resistant vaginal trichomoniasis. Nine patients -- four who were allergic to metronidazole and five whose infections were resistant to it -- took part in the study. The paromomycin cream, developed by Nyirjesy at Temple, was applied topically for two weeks. The result: six women were cured with the paromomycin cream alone and a seventh was cured with a combination of the cream and an antibiotic which had previously failed.
The study was conducted in collaboration with researchers at Wayne State University School of Medicine in Detroit. ìThe major impact of paromomycin cream is that it presents an effective, alternative treatment option for women with hard-to-treat vaginal trichomoniasis,î stated Nyirjesy.
###
RSS